×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen and Betta Pharma Announce Approval of Joint Venture in China

Amgen and Betta Pharmaceuticals Co., Ltd (Betta Pharma) have received the approval of relevant government authorities in China to create a joint venture between the two companies. The Hangzhou, China-based joint venture, officially launched on Sept. 26, 2013.  It will operate under the name Amgen-Betta Pharmaceuticals Co., Ltd. (贝达安进制药有限公司), and will be responsible for the introduction of Amgen’s Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Betta Pharma aim to quickly and efficiently deliver Vectibix® to patients in China, following regulatory approval of the medicine in China.